The Utrecht Monoclonal Antibody Facility (UMAB) is the antibody facility of UMC Utrecht, specializing in the generation of high-quality monoclonal antibodies targeting surface proteins.
Beyond their biological functions, monoclonal antibodies play a crucial role in biomedical research, diagnostics, and therapeutic development. Generating antibodies against low-immunogenic membrane proteins—such as multi-pass membrane proteins or targets with small extracellular domains—remains technically challenging.
To address this challenge, UMAB has developed a proprietary cell-based immunization method. In addition to antibody generation using hybridoma technology, UMAB is specialized in sequencing antibody variable regions, as well as the production and purification of newly generated monoclonal antibodies.
Interested in generating new antibodies for your target or have questions about our services? Please contact Jeanette Leusen.
UMAB was established in 2012 as a core facility of the Center for Translational Immunology (CTI) at UMC Utrecht.
The facility distinguishes itself from other antibody-generation platforms through its unique cellular immunization approach. In addition, UMAB serves as an informational and advisory resource for antibody-related research questions.
UMAB works closely with researchers to develop custom-made monoclonal antibodies tailored to specific scientific needs. All projects are conducted on a custom basis, and no intellectual property (IP) claims are made by the facility.
UMAB operates under ISO 9001 certification, ensuring consistent quality standards.